<DOC>
	<DOCNO>NCT00636818</DOCNO>
	<brief_summary>The primary objective clinical study ass overall safety tolerability measure discontinuation rate due adverse event dose 120 mg/day relation global clinical study adult subject meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM-IVâ„¢ ) criteria Attention-Deficit/Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>Atomoxetine Asian Study Adult Subjects With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>1. least 18 year age 2. meet Conners ' Adult ADHD Diagnostic Interview DSMIV ( CAADID ) diagnostic criterion current ADHD well meet criterion historical diagnosis ADHD childhood 3. Clinical Global ImpressionsADHDSeverity ( CGIADHDS ) score 4 ( moderate symptom ) great 1 . Patients meet DSMIV diagnostic criterion current major depression also patient total score 12 17item Hamilton Depression Rating Scale ( HAMD17 ) Visit 1 Visit 2 . Patients current past history major depression receive antidepression drug therapy within 6 month Visit 1 . 2 . Patients meet DSMIV diagnostic criterion current anxiety disorder also require antianxiety drug therapy except take benzodiazepine analogue anxiety need limit . 3 . Patients history bipolar disorder ( DSMIV ) , history schizophrenia history psychotic disorder ( DSMIV ) exclude study . 4 . Patients diagnose ( DSMIV ) pervasive developmental disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>